News Releases
Cannabix Technologies Provides Update on Marijuana Breathalyzer Development
January 23, 2018
Vancouver, British Columbia, January 23, 2018 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report development of its “Beta 3.0” (Cannabix Marijuana Breathalyzer) prototype device based on its FAIMS- (field asymmetric waveform ion mobility spectrometry) has been proceeding at a robust pace and is now complete. This device is designed to operate both independently or coupled in tandem directly to a conventional Quadrupole Mass Spectrometer (MS) device used in forensic labs.
The Beta 3.0 prototype incorporates several key technological improvements which include enhancements to the ion source which, for portability, has been reduced in size with sustained stability, providing improvements to transmission and overall device sensitivity. The Beta 3.0 prototype also incorporates its own tunable self-contained detector which can be used in both independent FAIMS operation or in “pass-through” mode for tandem coupling directly with a MS device.
Chief Scientific Officer, Dr. Raj Attariwala, states, “With completion of the modular Beta 3.0 prototype, Cannabix has achieved several key developmental milestones allowing this technology to be directly tested against the accepted laboratory standard of mass spectrometry”.
The Company has performed preliminary bench testing with the Beta 3.0 prototype and has successfully detected THC using the device in stand-alone mode with tandem MS analysis demonstrating direct correlation. This is a significant developmental milestone which the Company will use to optimize and characterize the device’s performance measures both independently and coupled to MS.
Cannabix has been on the leading edge in innovation with FAIMS technology built upon the current technique of MS for measuring THC. MS is considered the gold standard in toxicology in the analysis of drugs, poisons, and metabolites, due to its superior specificity and sensitivity. It is anticipated that any marijuana breathalyzer product will need to have its results be secondarily confirmed by independent MS. Recent work by Company scientists and engineers to allow the Cannabix Marijuana breathalyzer to easily couple to conventional MS equipment used in toxicology labs everywhere is a significant achievement.
Disclaimer:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
